Hookipa Total Operating Expenses from 2010 to 2024

HOOK Stock  USD 2.29  0.14  6.51%   
Hookipa Pharma Total Operating Expenses yearly trend continues to be quite stable with very little volatility. Total Operating Expenses may rise above about 61.5 M this year. Total Operating Expenses is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. View All Fundamentals
 
Total Operating Expenses  
First Reported
2018-03-31
Previous Quarter
23.6 M
Current Value
22.3 M
Quarterly Volatility
6.7 M
 
Covid
Check Hookipa Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hookipa Pharma's main balance sheet or income statement drivers, such as Tax Provision of 454.6 K, Net Interest Income of 4.8 M or Interest Income of 5.2 M, as well as many indicators such as Price To Sales Ratio of 3.61, Dividend Yield of 0.0 or PTB Ratio of 0.81. Hookipa financial statements analysis is a perfect complement when working with Hookipa Pharma Valuation or Volatility modules.
  
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

Latest Hookipa Pharma's Total Operating Expenses Growth Pattern

Below is the plot of the Total Operating Expenses of Hookipa Pharma over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Hookipa Pharma's Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hookipa Pharma's overall financial position and show how it may be relating to other accounts over time.
Total Operating Expenses10 Years Trend
Slightly volatile
   Total Operating Expenses   
       Timeline  

Hookipa Total Operating Expenses Regression Statistics

Arithmetic Mean35,838,870
Geometric Mean24,860,051
Coefficient Of Variation89.00
Mean Deviation27,432,226
Median12,088,000
Standard Deviation31,896,189
Sample Variance1017.4T
Range88M
R-Value0.75
Mean Square Error482.4T
R-Squared0.56
Significance0
Slope5,335,630
Total Sum of Squares14243.1T

Hookipa Total Operating Expenses History

202461.5 M
202332.7 M
202287.4 M
2021100.1 M
202072.9 M
201963 M
201823.2 M

About Hookipa Pharma Financial Statements

Hookipa Pharma investors utilize fundamental indicators, such as Total Operating Expenses, to predict how Hookipa Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Operating Expenses32.7 M61.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.67)
Revenue Per Share
4.403
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.20)
Return On Equity
(0.49)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.